开拓药业-B：截至2024年12月31日止年度之年度业绩公告

* 20241231 2024123120231231 202312310202412315.0KOSHINÉ 202312311,060.8905.585.4%20241231155.3 20231231938.9860.891.7%2024123178.1KX-826GT200292023123120241231 2023123189.027.230.6%2024123161.8 202312317.019.6280.3%2024123126.6 20241231147.42024123135.6 2024123120231231 5I-III1KT-939KX-826GT20029KT-9392024 KX-826 202421KX-826Ib/IIIKX-826 2024524KX-8261.0%KX-8261.0%IIIKX-8260.5%KX-8261.0%202464KX-826INCIMethylpyridinyl FluoromethoxybenzonitrileDimethyloxothiooxoimidazolidineINCI2024710KOSHINÉKX-82620241016KX-8261.0%IIII/IIIKX-8261.0%AGA 20241230KX-8261.0%III2412025 2025320KX-826III AR-PROTAC(GT20029) 2024421AR-PROTACGT20029IIa 2024617AR-PROTACGT20029IIIIGT20029 0.5%QD1%QDGT20029PK (KT-939) 20241029KT-939INCIKT-939Mono ID39815KT-939KT-939 5I-IIIKX-826GT20029II/IIIII 2024KOSHINÉKX-826KOSHINÉ5.0KX-826KT-9392025 KOSHINÉKOSHINÉ KX-826IIIIIIIIIKX-826KX-826Ib/IIIKX-8261.0%KX-826KX-826KX-8261.0%KX-8260.5%II GT20029PROTACIIPROTACGT20029IGT20029PKAR-PROTACGT20029IIaGT20029IIb/IIIIIAR-PROTACGT20029IIIIGT20029 0.5% QD1% QDGT20029 GT1708FIIPFII ARKX-826GT20029KOSHINÉmCRPCIPF 51KX-826AR-PROTAC(GT20029)Hedgehog/SMO(GT1708F)mTOR(GT0486)ALK-1(GT90001)KT-939 •KX-826 KX-826ARARAR KX-826203098KX-826 i. ARARARARRNA(mRNA)5-DHTARKX-826AR IIIIIIIIIIIITAHCII24 KX-826Ib/IIIKX-8261.0% 202421KX-826Ib/IIIKX-826KX-826 2024524KX-8261.0%KX-8261.0%IIIKX-8260.5%KX-8261.0% 202464KX-826INCIMethylpyridinylFluoromethoxybenzonitrile DimethyloxothiooxoimidazolidineINCIKX-826 2024710KOSHINÉKX-826KOSHINÉ 20241016KX-8261.0%IIII/IIIKX-8261.0%AGA 20241230KX-8261.0%III2412025 2025320KX-826III KX-8265216TEAETAHCKX-8260.5% BID —KX-826 —52TAHCTAHW(P<0.0001)52TAHC≥10/cm246%≥20/cm220% HGA52HGAHGA≥153%HGA48.4% ii. 9.4%20208FDA40ARAR KX-826ARARARARKX-826AR KX-826IIIIKX-826PK160PillsburyI-IIIIGA2–30.25% QDBID0.5% QDBIDQDBID 12IGA 5IGA0–1≥2≥30KX-826122KX-826KX-826 •AR-PROTAC(GT20029) GT20029GT20029PROTACAR-PROTACIIPROTACGT20029DHTPDGT20029PDGT20029 GT20029I IGT20029PK92GT20029GT20029PK0.001ng/mL140.05ng/mLTRAE11TRAE IGT20029SADMADPK123GT20029SADMADPKSAD(0.003 ng/mL)MAD14(Cmax)0.015 ng/mLSADGT20029TEAEMADTEAESAETEAETEAE AR-PROTACGT20029IIaAR-PROTACGT20029II 2024421AR-PROTACGT20029IIaIIaGT20029III1212TAHC180QDBIWGT200290.5%1% —QDBIWGT2002912GT20029 0.5% QDTAHC16.80/cm26.69/cm2(P<0.05)GT20029 1.0% BIWTAHC11.94/cm27.36/cm2(P<0.05)BIWGT20029 —GT20029 —GT20029 1% BIWIIIII 2024617AR-PROTACGT20029IIIIGT200290.5% QD1% QDGT20029PK GT1708FHedgehog/SMO GT1708FhedgehogIPF i.IPF IPFIPF35IPF10144310229GT1708FSMOHhHhIPFHhIPFIPFSMOGli1IPFHhSMOGli1GT1708FGli1Gli2-SMA SDGT1708FGT1708FGT1708F(P<0.001) 20231011GT1708FIPFII ii. 202358GT1708FHedgehog/SMOI IGT1708FPK1815AML3MDS20mg QD140mg QD180mg QD4120mg QD3180mg QD3240mg QD3320mg QD3SAEGT1708FTEAETEAE180mgAMLAML62% —65ASH 2023GT1708F ALK-1(GT90001) ALK-1IgG2ALK-1/TGF-20182ALK-1ALK-1ALK-1PD-1VEGF ALK-1NivolumabHCCII202277208(40.0%)ALK-1NivolumabHCCIIINDALK-1NivolumabHCC 20231028ALK-1PD-1NivolumabHCCIb/IIBMC11.806GT900017.0mg/kg2NivolumabHCCHCC GT0486 GT0486PI3K/mTORmTORHCCGT0486INDI C-Myc MycMycc-Myc2024313c-MycNatureNature Communications16.6MYCCDK4/6c-MycA80.2HCICDK4/6ASH 202364c-Myc KT-939 KT-939KT-939 20241029KT-939INCIKT-939Mono ID39815 PROTACALK-1/VEGF 18A.08(3)KX-826 ARARARARPK/PDARKX-8266KX-826TAHC22.7/cm2KX-826 PROTACPROTACPROTACGT20029GT20029IIaPROTACII 3 KX-826INCIKOSHINÉKX-826KX-826KOSHINÉ KOSHINÉ202412315.02023202412311,060.8155.3 202412315.020231231 202412319.7KOSHINÉ2023123142.2 2023123120.91.15.2%2024123121.99.01.0(i)7.1(ii)1.8 (i)(ii)(iii)202312317.019.6280.3%2024123126.6KOSHINÉ21.53.4 (i)(ii)(iii)(iv) 2023123189.027.230.6%2024123161.8(i)14.2(ii)7.2(iii)2.3(iv)2.8 (i)CRO(ii)(iii)(iv)CROCMO(v)(vi) 20231231938.9860.891.7%2024123178.1(i)603.9(ii)86.6(iii)73.0(iv)81.7 KX-826GT2002961.080%3.95% 202412315.9202312312.9 202312319.70.44.3%202412319.3 202412310.018Kintor Pharmaceutical Inc.202312318.0 202312311,060.8905.585.4%20241231155.3 2024123116845% 202320241231 2024123120231231456.3308.967.7%147.4(i)(ii) 20231231210.3%20241231103.0% 2024123114.435.6 20241231 20241231199.1195.29.35.50.02 20231231387.6385.412.110.20.3 2024123120.0(i)10.4(ii)10.0 202312313.3(i)137.7(ii)5.2(i)137.1(ii)2.7 20241231119.7(i)149.6(ii)4.7(i)34.3(ii)0.4 2023123133.5(i)99.4(ii)4.8(i)70.0(ii)0.8 20231231247.8202412315.1 20231231472.620241231171.7 2024123170.047.414.4111.8 2023123183.0144.120.0113.7 20241231 20241231 2024202312311,206,000 202412311212 202412315.1 20241231 2024202312311231 2024202312311231 515,126869,232 1 1.1 2018516Cricket Square, Hutchins Drive, PO Box2681, Grand Cayman, KY1-1111, Cayman Islands 2020522 2 2.1 (i) 622 (ii) (iii) 20241231155,292,000199,080,000202412315,051,000111,763,00053,111,000147,419,000 20241231 (i)2025370,000,00035,000,000 (ii)(iii)(iv) 2024123120241231 (i)(iv) (i)(ii)(iii)(iv) (a) 202411 (b) 202411 3 (a) 10% —— (i) Kintor Science LimitedKoshine Pharmaceutical